Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply� and “GSK insider trading Form 4 transactions.�
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc has filed a Form 6-K to meet Financial Conduct Authority (FCA) Disclosure Guidance & Transparency Rule 5.6.1R. As of 31 July 2025 the company had 4,315,385,410 issued Ordinary Shares of 31 ¼ pence each. Of these, 237,044,421 shares were held in treasury, leaving 4,078,340,989 voting rights in circulation. Shareholders should use this denominator when calculating threshold notifications of holdings under FCA rules. The notice was authorised by Company Secretary V. A. Whyte and filed on 1 August 2025.
GSK plc filed a Form 6-K detailing a routine share repurchase executed on 31 July 2025 under its June-2025 non-discretionary buy-back mandate.
- Shares bought: 474,100 ordinary shares (nominal 31¼ p).
- Price range: 1,404.50â€�1,461.00&²Ô²ú²õ±è;³Òµþ±è; VWAP 1,423.11 GBp.
- Cumulative purchases since 4 June 2025: 18,910,038 shares.
The shares will be held in treasury, increasing the treasury balance to 237,044,421. Shares in issue (excluding treasury) now total 4,078,340,989, establishing the new denominator for voting-rights disclosures. Treasury stock represents 5.81 % of total voting rights.
No operational, earnings or guidance updates were provided; the filing primarily fulfils UK DTR 5.5.1R disclosure requirements.
Q2-25 snapshot: GSK generated turnover of £7.99 bn (+1% AER, +6% CER), led by Specialty Medicines (£3.33 bn, +15% CER) and Vaccines (£2.09 bn, +9% CER). Core operating profit rose 12% to £2.63 bn, lifting core margin 1.8 ppts to 32.9%; core EPS advanced 15% to 46.5 p. Total EPS climbed 35% on lower contingent-consideration charges. Cash generated from operations grew 47% to £2.43 bn, translating into £1.13 bn of free cash flow.
Guidance & capital returns: Management now expects FY-25 turnover, core operating profit and core EPS to reach the top end of prior 3-5%, 6-8% and 6-8% CER ranges. A 16 p dividend was declared (64 p FY target) and £822 m of a £2 bn buy-back executed in H1.
Pipeline momentum: Three FDA approvals received YTD (Penmenvy, Blujepa, Nucala-COPD); five major approvals targeted in 2025, with 14 late-stage assets each aiming for >£2 bn PYS. Phase III tebipenem stopped early for efficacy.
Key watch-points: General Medicines declined 6% CER, U.S. Shingrix demand softened and pricing pressure from U.S. IRA persisted. Core R&D spend increased 11% and included a £471 m impairment (belrestotug). Net debt edged to £13.7 bn after £0.8 bn acquisitions, £1.3 bn dividends and £0.8 bn buy-backs.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
